Pfizer Inc. (PFE) Thursday reported positive topline results from the Phase 3 TALAPRO-2 study of Talzenna in combination with Xtandi in patients with metastatic castration-resistant prostate cancer (mCRPC).
Results from the study showed that Talzenna plus Xtandi demonstrated statistically significant overall survival (OS) benefit in patients with mCRPC compared to Xtandi alone.
Talzenna in combination with Xtandi is already approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with HRR gene-mutated mCRPC. The combination is also approved by the European Commission to treat adults with mCRPC in whom chemotherapy is not clinically indicated.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.